Monoclonal antibodies to B and T lymphocyte attenuator (BTLA) have no effect on in vitro B cell proliferation and act to inhibit in vitro T cell proliferation when presented in a cis, but not trans, format relative to the activating stimulus

Clinical and Experimental Immunology

Volumn 163, Issue 1, 2011, Pages 77-87

  Zhang, M ^a   Howard, K ^a   Winters, A ^a   Steavenson, S ^a   Anderson, S ^a   Smelt, S ^a   Doellgast, G ^a   Sheelo, C ^a   Stevens, J ^a   Kim, H ^a   Hamburger, A ^a   Sein, A ^a   Caughey, D J ^a   Lee, F ^a   Hsu, H ^a   Siu, G ^b   Byrne, F R ^a  

^a AMGEN INC   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Activation; B lymphocyte; BTLA; Cross linking; Inhibition; T lymphocyte

Indexed keywords

B AND T LYMPHOCYTE ATTENUATOR; CD3 ANTIGEN; CROSS LINKING REAGENT; HERPESVIRUS ENTRY MEDIATOR LIGAND; IMMUNOGLOBULIN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; LYMPHOTOXIN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CROSS LINKING; HUMAN; IMMUNOGLOBULIN M DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; LIGHT; LYMPHOCYTE ACTIVATION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ANTIGENS, CD40; B-LYMPHOCYTES; CROSS-LINKING REAGENTS; IMMUNOGLOBULIN M; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOTOXIN-ALPHA; MICE; MICE, INBRED BALB C; RECEPTORS, IMMUNOLOGIC; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 14; T-LYMPHOCYTES;

EID: 78649734504     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04259.x     Document Type: Article

References (34)

1. Gavrieli M, Watanabe N, Loftin SK, Murphy TL, Murphy KM. Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2. Biochem Biophys Res Commun 2003; 312:1236-43.
2. Hurchla MA, Sedy JR, Drake CG, Murphy KM. B and T lymphocytle attenuator (BTLA) exhibits structural and expression polymorphisms and is highly Induced in anergic CD4+ T cells. J Immunol 2005; 174:3377-85.
3. Compaan DM, Gonzalez LC, Tom I, Loyet KM, Eaton D, Hymowitz SG. Attenuating lymphocyte activity - the crystal structure of the BTLA-HVEM complex. J Biol Chem 2005; 280:39553-61.
4. Hurchla MA, Sedy JR, Murphy KM. Unexpected role of B and T lymphocyte attenuator in sustaining cell survival during chronic allostimulation. J Immunol 2007; 178:6073-82.
5. Chemnitz JM, Lanfranco AR, Braunstein I, Riley JL. B and T lymphocyte attenuator-mediated signal transduction provides a potent inhibitory signal to primary human CD4 T cells that can be initiated by multiple phosphotyrosine motifs. J Immunol 2006; 176:6603-14.
6. Cai GF, Anumanthan A, Brown JA, Greenfield EA, Zhu B, Freeman GJ. CD160 inhibits activation of human CD4(+) T cells through interaction with herpesvirus entry mediator. Nat Immunol 2008; 9:176-85.
7. Krieg C, Boyman O, Fu Y-X, Kaye J. B and T lymphocyte attenuator regulates CD8(+) T cell-intrinsic homeostasis and memory cell generation. Nat Immunol 2007; 8:162-71.
8. Krieg C, Han P, Stone R, Goularte OD, Kaye J. Functional analysis of B and T lymphocyte attenuator engagement on CD4(+) and CD8(+) T cells. J Immunol 2005; 175:6420-7.
9. Sedy JR, Gavrieli M, Potter KG et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005; 6:90-8.
10. Tao R, Wang L, Han R et al. Differential effects of B and T lymphocyte attenutator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts. J Immunol 2005; 175:5774-82.
11. Tao R, Wang L, Murphy KM, Fraser CC, Hancock WW. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. J Immunol 2008; 180:6649-55.
12. An M-M, Fan K-X, Zhang J-D et al. Lymphtoxin beta receptor-Ig ameliorates TNBS-induced colitis via blocking LIGHT/HVEM signaling. Pharmacol Res 2005; 52:234-44.
13. Brown GR, Lee EL, El-Hayek J, Kintner K, Luck C. IL-12-independent LIGHT signaling enhances MHC class II disparate CD4+ T cell alloproliferation, IFN-gamma response, and intestinal graft-versus-host disease. J Immunol 2005; 174:4688-95.
14. Tamada K, Ni J, Zhu G et al. Cutting edge: selective impairment of CD8+ T cell function in mice lacking the TNF superfamily member LIGHT. J Immunol 2002; 168:4832-5.
15. Tamada K, Shimozaki K, Chapoval AI et al. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol 2000; 164:4105-10.
16. Ye Q, Fraser CC, Gao W et al. Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival. J Exp Med 2002; 195:795-800.
17. Cheung TC, Humphreys IR, Potter KG et al. Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway. Proc Natl Acad Sci USA 2005; 102:13218-23.
18. Cheung TC, Macauley MG, Oborne LM, Ware CF. Dimerization of HVEM and BTLA in cellular membranes. Cytokine 2008; 43:294.
19. Cheung TC, Steinberg MW, Oborne LM et al. Unconventional ligand activation of herpesvirus entry mediator signals cell survival. Proc Natl Acad Sci USA 2009; 106:6244-9.
20. Arav-Boger R, Foster CB, Zong J-C, Pass RF. Human cytomegalovirus-encoded alpha-chemokines exhibit high sequence variability in congenitally infected newborns. J Infect Dis 2006; 193:788-91.
21. Arav-Boger R, Willoughby RE, Pass RF et al. Polymorphisms of the cytomegalovirus (CMV)-encoded tumor necrosis factor-alpha and beta-chemokine receptors in congenital CMV disease. J Infect Dis 2002; 186:1057-64.
22. Bale JF, Petheram SJ, Robertson M, Murph JR, Demmler G. Human cytomegalovirus alpha sequence and UL144 variability in strains from infected children. J Med Virol 2001; 65:90-6.
23. Picone O, Costa JM, Chaix ML, Ville Y, Rouzioux C, Leruez-Ville M. Human cytomegalovirus UL144 gene polymorphisms in congenital infections. J Clin Microbiol 2005; 43:25-9.
24. Prichard MN, Penfold MET, Duke GM, Spaete RR, Kemble GW. A review of genetic differences between limited and extensively passaged human cytomegalovirus strains. Rev Med Virol 2001; 11:191-200.
25. Stranska R, Schuurman R, Toet M, Verboon-Maciolek M, De Vries LS, Van Loon AA. Application of UL144 molecular typing to determine epidemiology of cytomegalovirus infections in preterm infants. J Clin Microbiol 2006; 44:1108-10.
26. Mei L, Taylor KD, Landers CJ, McGovern DP, Targan SR, Rotter JI. Genetic variation in BTLA is strongly associated with Crohn's disease. Gastroenterology 2008; 1:A42.
27. Lin SC, Kuo CC, Chan CH. Association of a BTLA gene polymorphism with the risk of rheumatoid arthritis. J Biomed Sci 2006; 13:853-60.
28. Wang J, Anders RA, Wang Y et al. The critical role of LIGHT in promoting intestinal inflammation and Crohn's disease. J Immunol 2005; 174:8173-82.
29. Byrne FR, Winters A, Brankow D et al. An antibody to IP-10 is a potent antagonist of cell migration in vitro and in vivo and does not affect disease in several animal models of inflammation. Autoimmunity 2009; 42:171-82.
30. Wu T-H, Zhen Y, Zeng C, Yi H-F, Zhao Y. B and T lymphocyte attenuator interacts with CD3zeta and inhibits tyrosine phosphorylation of TCRzeta complex during T-cell activation. Immunol Cell Biol 2007; 85:590-5.
31. Gonzalez LC, Loyet KM, Calemine-Fenaux J et al. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc Natl Acad Sci USA 2005; 102:1116-21.
32. Owada T, Watanabe N, Oki M et al. Activation-induced accumulation of B and T lymphocyte attenuator to the immunological synapse in CD4+ T cells. J Leukoc Biol 2010; 87:425-32.
33. Finkelman FD, Morris SC. Development of an assay to measure in vivo cytokine production in the mouse. Int Immunol 1999; 11:1811-18.
34. Truong W, Plester JC, Hancock WW et al. Combined coinhibitory and costimulatory modulation with anti-BTLA and CTLA4Ig facilitates tolerance in murine islet allografts. Am J Transpl 2007; 7:2663-74.